Ceribell
Mountain View
About Ceribell
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $50K – $100K
- Total funding: $171.0M
- Funding stage: IPO
- Last round: Series C (Sep 2022)
- Ticker: nasdaq:CBLL
- Website: ceribell.com
- Phone: +1 800-763-0183
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/ceribell-2442 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.